Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

Survival of Persons Living With HIV/AIDS: A Multicentric Study From India

Author(s): Sanjeev Sinha*, Sameer Abdul Samad, Garima Bansal, Saurav Verma, Shashikala Anant Sangle, Subhasish Kamal Guha, Neetu Rajput, Ravindra Mohan Pandey, Sanjay Ranjan, Sonali Salvi, Sanjay Mundhe, Monika More, Dolanchampa Modak, Kalpana Datta, S.K. Kabra, Rakesh Lodha, Neeraj Nischal and Bimal Kumar Das

Volume 21, Issue 1, 2023

Published on: 22 February, 2023

Page: [81 - 87] Pages: 7

DOI: 10.2174/1570162X21666230123151639

Price: $65

Abstract

Background: It has been more than 17 years since the introduction of free ART in India. At this point, it would be prudent to look at the factors associated with the survival of persons living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLHA) who are already enrolled in the ART program.

Methods: PLHAs enrolled from antiretroviral therapy (ART) centers located in three different cities in India – Delhi, Pune and Kolkata, and were followed up at six monthly intervals monitoring the WHO stage, CD4 counts, complete blood counts, and liver and kidney function tests, for a duration of three years.

Results and Discussion: The incidence of mortality among HIV/AIDS patients on ART was 5.0 per 1000 patient-years (21/1410, 1.4%). Age at initiation of ART, being above 35 years, was the only significant predictor of mortality (log-rank p = 0.018). Multivariable analysis showed a significant association of an unfavourable outcome (defined as mortality or development of opportunistic infection during follow-up) with male gender (adjusted odds ratio (AOR) = 5.26, p = <0.01) and being unmarried at ART initiation (AOR = 1.39, p = 0.005).

Conclusion: The survival of PLHA with good adherence to ART is independent of the WHO stage or CD4 counts at the initiation of ART. Initiation of ART after 35 years of age was a significant predictor of mortality.

Keywords: HIV, AIDS, PLHA, WHO, complete blood counts, survival.

« Previous
Graphical Abstract
[1]
World Health Organization.. Key facts and latest estimates on the global HIV epidemic. 2021. Available from: https://www.who.int/ news-room/fact-sheets/detail/hiv-aids
[2]
National AIDS Control Organization & ICMR-National Institute of Medical Statistics.. India HIV Estimates 2021: Fact Sheet. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. 2022. Available from: http://naco.gov.in/surveillance-epidemiology-0
[3]
Setia MS, Acharya S, Palkar A, Keskar P. Factors associated with survival in adult people living with HIV/AIDS (PLHAs) in Mumbai, India (2004-2019): A retrospective cohort study. J Family Med Prim Care 2021; 10(2): 758-64.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_1703_20] [PMID: 34041073]
[4]
Abuto W, Abera A, Gobena T, Dingeta T, Markos M. Survival and predictors of mortality among HIV positive adult patients on highly active antiretroviral therapy in public hospitals of Kambata Tambaro Zone, Southern Ethiopia: A retrospective cohort study. HIV AIDS (Auckl) 2021; 13: 271-81.
[http://dx.doi.org/10.2147/HIV.S299219] [PMID: 33737838]
[5]
Bijker R, Kiertiburanakul S, Kumarasamy N, et al. Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART. Antivir Ther 2020; 25(3): 131-42.
[http://dx.doi.org/10.3851/IMP3358] [PMID: 32369040]
[6]
Mangal TD, Meireles MV, Pascom ARP, de Almeida Coelho R, Benzaken AS, Hallett TB. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infect Dis 2019; 19(1): 206.
[http://dx.doi.org/10.1186/s12879-019-3844-3] [PMID: 30819120]
[7]
Chakravarty J, Tiwary NK, Prasad SR, et al. Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. Indian J Med Res 2014; 140(4): 491-500.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277134
[PMID: 25488442]
[8]
Kyaw NTT, Kumar AMV, Oo MM, et al. Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar. Glob Health Action 2017; 10(1): 1290916.
[http://dx.doi.org/10.1080/16549716.2017.1290916] [PMID: 28594295]
[9]
Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371(9622): 1417-26.
[http://dx.doi.org/10.1016/S0140-6736(08)60423-7] [PMID: 18387667]
[10]
Birhanu H, Alle A, Birhanu MY. Rate and predictors of mortality among adults on antiretroviral therapy at debre markos referral hospital, North West Ethiopia. HIV AIDS (Auckl) 2021; 13: 251-9.
[http://dx.doi.org/10.2147/HIV.S294111] [PMID: 33688265]
[11]
Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188(4): 571-7.
[http://dx.doi.org/10.1086/377135] [PMID: 12898445]
[12]
Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29(1): 150-4.
[http://dx.doi.org/10.1086/520144] [PMID: 10433578]
[13]
Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160(5): 293-300.
[http://dx.doi.org/10.7326/M13-1133] [PMID: 24737271]
[14]
Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020; 17(6): 601-14.
[http://dx.doi.org/10.1007/s11904-020-00531-0] [PMID: 32984925]
[15]
Abioye AI, Andersen CT, Sudfeld CR, Fawzi WW. Anemia, iron status, and HIV: A systematic review of the evidence. Adv Nutr 2020; 11(5): 1334-63.
[http://dx.doi.org/10.1093/advances/nmaa037] [PMID: 32383731]
[16]
Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr 2012; 12(1): 170.
[http://dx.doi.org/10.1186/1471-2431-12-170] [PMID: 23114115]
[17]
Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37(2): 292-8.
[http://dx.doi.org/10.1086/375844] [PMID: 12856222]
[18]
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92(7): 2506-12.
[http://dx.doi.org/10.1210/jc.2006-2190] [PMID: 17456578]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy